A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection

Anna Nilsson, John Pullman, Piotr Napora, Kléber Giovanni Luz, Anil Kumar Gupta, Jorge Draghi, Ana Karla Guzman Romero, Naresh Aggarwal, Galina Petrova, Juliana Ianus, Leen Vijgen, Jane Scott, Rekha Sinha, Sarah Rusch, Dymphy Huntjens, Kristi Bertzos, Marita Stevens